Differenze

Queste sono le differenze tra la revisione selezionata e la versione attuale della pagina.

Link a questa pagina di confronto

Entrambe le parti precedenti la revisione Revisione precedente
Prossima revisione
Revisione precedente
Ultima revisione Entrambe le parti successive la revisione
aree:proteomica:rppa:bibliografia [2017/02/16 21:15]
Gianluca Frustagli Nuova edizione
aree:proteomica:rppa:bibliografia [2017/02/18 22:36]
Gianluca Frustagli Aggiunta dei primi 11 link
Linea 12: Linea 12:
 ===== Bibliografia ===== ===== Bibliografia =====
  
-Signore M et al. \\ +Signore M et al. \\ 
-UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​27286453|UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.]] \\ 
-Oncotarget. 2016 Jul 12;​7(28):​44113-44128. doi: 10.18632/​oncotarget.9859.+<wrap lo>Oncotarget. 2016 Jul 12;​7(28):​44113-44128. doi: 10.18632/​oncotarget.9859.</​wrap>​
  
-De Angelis ML et al. \\ +De Angelis ML et al. \\ 
-Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​26956206|Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.]] \\ 
-Stem Cells Transl Med. 2016 Apr;​5(4):​511-23. doi: 10.5966/​sctm.2015-0214.+<wrap lo>Stem Cells Transl Med. 2016 Apr;​5(4):​511-23. doi: 10.5966/​sctm.2015-0214.</​wrap>​
  
-Marziali G, Signore M et al. \\ +Marziali G, Signore M et al. \\ 
-Metabolic/​Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​26857460|Metabolic/​Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.]] \\ 
-Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/​srep21557.+<wrap lo>Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/​srep21557.</​wrap>​
  
-Trono P et al. \\ +Trono P et al. \\ 
-hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​25961924|hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.]] \\ 
-Oncogene. 2016 Feb 18;​35(7):​887-96. doi: 10.1038/​onc.2015.143. Epub 2015 May 11.+<wrap lo>Oncogene. 2016 Feb 18;​35(7):​887-96. doi: 10.1038/​onc.2015.143. Epub 2015 May 11.</​wrap>​
  
-Signore M et al. \\ +Signore M et al. \\ 
-Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​24810059|Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.]] \\ 
-Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/​cddis.2014.188.+<wrap lo>Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/​cddis.2014.188.</​wrap>​
  
-Forte S et al. \\ +Forte S et al. \\ 
-Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​24349068|Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.]] \\ 
-PLoS One. 2013 Dec 12;​8(12):​e81432. doi: 10.1371/​journal.pone.0081432.+<wrap lo>PLoS One. 2013 Dec 12;​8(12):​e81432. doi: 10.1371/​journal.pone.0081432.</​wrap>​
  
-Sette G et al. \\ +Sette G et al. \\ 
-EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​23056514|EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.]] \\ 
-PLoS One. 2012;​7(10):​e46891. doi: 10.1371/​journal.pone.0046891.+<wrap lo>PLoS One. 2012;​7(10):​e46891. doi: 10.1371/​journal.pone.0046891.</​wrap>​
  
-Francescangeli F et al. \\ +Francescangeli F et al. \\ 
-Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​22753241|Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.]] \\ 
-Stem Cells. 2012 Sep;​30(9):​1819-30. doi: 10.1002/​stem.1163.+<wrap lo>Stem Cells. 2012 Sep;​30(9):​1819-30. doi: 10.1002/​stem.1163.</​wrap>​
  
-Signore M, Reeder KA. \\ +Signore M, Reeder KA. \\ 
-Antibody validation by Western blotting. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​22081344|Antibody validation by Western blotting.]] \\ 
-Methods Mol Biol. 2012;​823:​139-55. doi: 10.1007/​978-1-60327-216-2_10.+<wrap lo>Methods Mol Biol. 2012;​823:​139-55. doi: 10.1007/​978-1-60327-216-2_10.</​wrap>​
  
-Napoletani D et al. \\ +10 Napoletani D et al. \\ 
-Homologous control of protein signaling networks. \\ +[[https://​www.ncbi.nlm.nih.gov/​pubmed/​21439301|Homologous control of protein signaling networks.]] \\ 
-J Theor Biol. 2011 Jun 21;​279(1):​29-43. doi: 10.1016/​j.jtbi.2011.03.020.+<wrap lo>J Theor Biol. 2011 Jun 21;​279(1):​29-43. doi: 10.1016/​j.jtbi.2011.03.020.</​wrap>​
  
-VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\ +11 VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. \\ 
-Reverse-phase protein microarrays:​ application to biomarker discovery and translational medicine. \\ +[https://​www.ncbi.nlm.nih.gov/​pubmed/​17892368[|Reverse-phase protein microarrays:​ application to biomarker discovery and translational medicine.]] \\ 
-Expert Rev Mol Diagn. 2007 Sep;​7(5):​625-33. Review.+<wrap lo>Expert Rev Mol Diagn. 2007 Sep;​7(5):​625-33. Review.</​wrap>​
  
 Spreafico F et al. \\ Spreafico F et al. \\
-Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread. \\ +[[|Proteomics analysis of cerebrospinal fluid from children with Central Nervous System tumors identifies candidate proteins relating to tumor metastatic spread.]] \\ 
-Oncotarget (submitted, second round of revision)+<wrap lo>Oncotarget (submitted, second round of revision)</​wrap>​
  
 Manic G & Signore M et al. \\ Manic G & Signore M et al. \\
-CHK1-targeted therapy to deplete DNA replication-stressed,​ p53-deficient hyperdiploid colorectal cancer stem cells. \\ +[[|CHK1-targeted therapy to deplete DNA replication-stressed,​ p53-deficient hyperdiploid colorectal cancer stem cells.]] \\ 
-Gut (submitted, second round of revision)+<wrap lo>Gut (submitted, second round of revision)</​wrap>​
  
 Haas TL et al. \\ Haas TL et al. \\
-Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme. \\ +[[|Identification of Integrin Alpha 7 as Functional Marker and Potential Therapeutic Target in Glioblastoma Multiforme.]] \\ 
-Cell Stem Cell (submitted, second round of revision)+<wrap lo>Cell Stem Cell (submitted, second round of revision)</​wrap>​ 
 + 
 +FIXME Aggiungere link agli articoli